Indication
Synovial
1 clinical trial
2 products
2 drugs
Clinical trial
A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersStatus: Recruiting, Estimated PCD: 2027-12-30
Product
CyclophosphamideDrug
cyclophosphamideProduct
HBI 0201-ESO TCRTDrug
interleukin-2